Seeking Alpha

Keryx Biopharmaceuticals (KERX) announces that results from a Phase 3 trial of its perifosine...

Keryx Biopharmaceuticals (KERX) announces that results from a Phase 3 trial of its perifosine drug failed to meet primary endpoints for improving survivability of patients with refractory advanced colorectal cancer. Shares -58.6% premarket.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs